Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 132 of the 133 references it cites were found in a registry or an index; 40 of the 58 sources its claims cite were checked for support.

Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata

Open access

Abstract

The evolution of drug resistance has a profound impact on human health. Candida glabrata is a leading human fungal pathogen that can rapidly evolve resistance to echinocandins, which target cell wall biosynthesis and are front-line therapeutics for Candida infections. Here, we provide the first global analysis of mutations accompanying the evolution of fungal drug resistance in a human host utilizing a series of C. glabrata isolates that evolved echinocandin resistance in a patient treated with the echinocandin caspofungin for recurring bloodstream candidemia. Whole genome sequencing identified a mutation in the drug target, FKS2, accompanying a major resistance increase, and 8 additional non-synonymous mutations. The FKS2-T1987C mutation was sufficient for echinocandin resistance, and associated with a fitness cost that was mitigated with further evolution, observed in vitro and in a murine model of systemic candidemia. A CDC6-A511G(K171E) mutation acquired before FKS2-T1987C(S663P), conferred a small resistance increase. Elevated dosage of CDC55, which acquired a C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated fitness. To discover strategies to abrogate echinocandin resistance, we focused on the molecular chaperone Hsp90 and downstream effector calcineurin. Genetic or pharmacological compromise of Hsp90 or calcineurin function reduced basal tolerance and resistance. Hsp90 and calcineurin were required for caspofungin-dependent FKS2 induction, providing a mechanism governing echinocandin resistance. A mitochondrial respiration-defective petite mutant in the series revealed that the petite phenotype does not confer echinocandin resistance, but renders strains refractory to synergy between echinocandins and Hsp90 or calcineurin inhibitors. The kidneys of mice infected with the petite mutant were sterile, while those infected with the HSP90-repressible strain had reduced fungal burden. We provide the first global view of mutations accompanying the evolution of fungal drug resistance in a human host, implicate the premier compensatory mutation mitigating the cost of echinocandin resistance, and suggest a new mechanism of echinocandin resistance with broad therapeutic potential.

Overview

CoChat Summary

## TL;DR

This study tracks echinocandin resistance as it evolved over 10 months in a patient with recurrent *Candida glabrata* candidemia, using whole-genome sequencing plus functional genetics. The main resistance mutation was *FKS2* T1987C (S663P), which was sufficient for resistance but carried a fitness cost that was later mitigated; the paper also shows that Hsp90 and calcineurin are required for resistance and for caspofungin-induced *FKS2* expression.

## Key findings

  • Whole-genome sequencing of early isolate A and late isolate G found 26 single-nucleotide variants total, with 17 in open reading frames and 9 non-synonymous mutations; these were mapped across the 7-isolate series.
  • The *FKS2* T1987C (S663P) mutation was sufficient to confer echinocandin resistance in a susceptible laboratory strain, but it reduced fitness in RPMI at 37°C; the paper reports this fitness cost was mitigated with further evolution.
  • A *CDC6* A511G (K171E) mutation conferred a small increase in echinocandin resistance, and increased dosage of *CDC55* ameliorated the fitness cost associated with the *FKS2* mutation.
  • Pharmacological or genetic compromise of Hsp90 or calcineurin reduced basal tolerance/resistance, and caspofungin-induced *FKS2* expression was blocked by deletion of *CNB1* and reduced when *HSP90* was repressed.
  • A petite mutant in the series was not intrinsically echinocandin-resistant, but was refractory to the synergy between caspofungin and Hsp90/calcineurin inhibitors; in mice, kidneys infected with the petite mutant were sterile, and reduced *HSP90* lowered kidney fungal burden.

## Methods

  • Clinical case series: 7 related *C. glabrata* bloodstream isolates collected over a 10-month period from one patient with recurrent candidemia during caspofungin treatment.
  • Genomics and validation: whole-genome sequencing of isolates A and G on Illumina Genome Analyzer II (5.1 and 3.8 million 76-bp reads; 22–30× coverage), alignment to CBS138, variant calling, Sanger validation, and Sanger mapping of candidate mutations across isolates B–F.
  • Functional assays: broth microdilution MIC testing, qRT-PCR for *FKS2*, *CNB1*, and *HSP90* expression, growth-curve analysis, engineered mutant/complement strains, and a murine disseminated infection model in CD1 mice (n = 10 per group).

## Limitations

  • The paper states that whether the original petite mutant arose in the human host or during sampling “remains unknown.”
  • The authors note that methionine levels in mice may not have been sufficient to fully repress the MET3 promoter, which may explain why *HSP90* depletion caused only a modest reduction in fungal burden in vivo.
  • Evident from the text: the study centers on a single patient case series, so the clinical evolutionary trajectory is detailed but not shown to be broadly representative.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1002718

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Non-synonymous mutations that accumulate in C. glabrata during the evolution of echinocandin resistance in a human host. C. glabrata clinical isolates display a step-wise increase in caspofungin resistance in a Minimum Inhibitory Concentration (MIC) assay. Isolates are arranged in the same order as they were recovered from the patient, where isolate A was recovered pre-treatment and isolate G was recovered after multiple rounds of caspofungin treatment. Assays were performed in RPMI medium with 2% glucose at 30°C for 72 hours. Optical densities were averaged for duplicate measurements and normalized relative to caspofungin-free controls (see color bar). The nine non-synonymous mutations identified in isolate G compared to isolate A using whole genome sequencing (marked in red) were mapped across isolates B to F using Sanger sequencing. Mutations in MOH1, GPH1, CDC6, and TCB1/2 occur between isolates B and C, which correspond to a small increase in echinocandin resistance, outlined in blue boxes. Mutations in DOT6, MRPL11, FKS2, and SUI2 correspond to a sharp increase in echinocandin resistance, outlined in black boxes.
Figure 1 Non-synonymous mutations that accumulate in C. glabrata during the evolution of echinocandin resistance in a human host. C. glabrata clinical isolates display a step-wise increase in caspofungin resistance in a Minimum Inhibitory Concentration (MIC) assay. Isolates are arranged in the same order as they were recovered from the patient, where isolate A was recovered pre-treatment and isolate G was recovered after multiple rounds of caspofungin treatment. Assays were performed in RPMI medium with 2% glucose at 30°C for 72 hours. Optical densities were averaged for duplicate measurements and normalized relative to caspofungin-free controls (see color bar). The nine non-synonymous mutations identified in isolate G compared to isolate A using whole genome sequencing (marked in red) were mapped across isolates B to F using Sanger sequencing. Mutations in MOH1, GPH1, CDC6, and TCB1/2 occur between isolates B and C, which correspond to a small increase in echinocandin resistance, outlined in blue boxes. Mutations in DOT6, MRPL11, FKS2, and SUI2 correspond to a sharp increase in echinocandin resistance, outlined in black boxes.CC BY · PubMed Central
Figure 2 The FKS2 T1987C (Fks2 S663P) mutation is sufficient for echinocandin resistance in a C. glabrata laboratory strain and imparts a fitness cost in the absence of the drug. (A) The FKS2 T1987C (Fks2 S663P) mutation uncovered in caspofungin-resistant clinical isolate G was introduced into a sensitive laboratory C. glabrata strain BG2 via single-stranded DNA containing a silent marker. Resistance profiles of three independent sequence-verified transformants were tested via MIC. MIC assays were performed in Figure 1 and plotted graphically as caspofungin concentration (µg/ml) versus optical density at 600 nm. (B) Growth kinetics of the BG2 laboratory strain of C. glabrata and three independent transformants harbouring a mutant FKS2 T1987C allele (left panel) and of the C. glabrata clinical isolate series (right panel). Growth curves were performed in RPMI medium at 37°C with orbital shaking, with measurements taken every 15 minutes for 48 hours.
Figure 2 The FKS2 T1987C (Fks2 S663P) mutation is sufficient for echinocandin resistance in a C. glabrata laboratory strain and imparts a fitness cost in the absence of the drug. (A) The FKS2 T1987C (Fks2 S663P) mutation uncovered in caspofungin-resistant clinical isolate G was introduced into a sensitive laboratory C. glabrata strain BG2 via single-stranded DNA containing a silent marker. Resistance profiles of three independent sequence-verified transformants were tested via MIC. MIC assays were performed in Figure 1 and plotted graphically as caspofungin concentration (µg/ml) versus optical density at 600 nm. (B) Growth kinetics of the BG2 laboratory strain of C. glabrata and three independent transformants harbouring a mutant FKS2 T1987C allele (left panel) and of the C. glabrata clinical isolate series (right panel). Growth curves were performed in RPMI medium at 37°C with orbital shaking, with measurements taken every 15 minutes for 48 hours.CC BY · PubMed Central
Figure 3 Increased dosage of CDC55 compensates for the fitness cost associated with the echinocandin resistance mutation FKS2 T1987C (Fks2 S663P) in C. glabrata. Either the wild-type (WT) CDC55 allele of clinical isolate A or the CDC55 C463T (Cdc55 P155S) allele of the late resistant clinical isolate G was expressed on a plasmid under the control of its native promoter in a C. glabrata laboratory strain harbouring the echinocandin resistance mutation FKS2 T1987C (Fks2 S663P). Growth kinetics of two independent transformants harbouring the FKS2 T1987C mutant allele and either the CDC55 C463T or CDC55 WT ectopically expressed allele, as well as a control strain harbouring an empty vector, were assessed. Growth curves were performed in RPMI medium at 37°C with orbital shaking, with measurements taken every 15 minutes for 48 hours.
Figure 3 Increased dosage of CDC55 compensates for the fitness cost associated with the echinocandin resistance mutation FKS2 T1987C (Fks2 S663P) in C. glabrata. Either the wild-type (WT) CDC55 allele of clinical isolate A or the CDC55 C463T (Cdc55 P155S) allele of the late resistant clinical isolate G was expressed on a plasmid under the control of its native promoter in a C. glabrata laboratory strain harbouring the echinocandin resistance mutation FKS2 T1987C (Fks2 S663P). Growth kinetics of two independent transformants harbouring the FKS2 T1987C mutant allele and either the CDC55 C463T or CDC55 WT ectopically expressed allele, as well as a control strain harbouring an empty vector, were assessed. Growth curves were performed in RPMI medium at 37°C with orbital shaking, with measurements taken every 15 minutes for 48 hours.CC BY · PubMed Central
Figure 4 Polymorphisms in MOH1 and CDC6 are prevalent in C. glabrata clinical isolates with FKS2-mediated echinocandin resistance. Genomic regions harbouring the 9 non-synonymous mutations uncovered in isolate G relative to isolate A were sequenced by Sanger sequencing in 10 unrelated C. glabrata echinocandin-resistant clinical isolates containing the resistance mutation FKS2 T1987C/Fks2 S663P. Synonymous mutations are in black font; non-synonymous mutations are in red with amino acid mutations listed in parentheses. Sequences were compared to both the reference CBS138 sequence as well as a control sample sequenced from the laboratory isolate BG2 (CgLC1272).
Figure 4 Polymorphisms in MOH1 and CDC6 are prevalent in C. glabrata clinical isolates with FKS2-mediated echinocandin resistance. Genomic regions harbouring the 9 non-synonymous mutations uncovered in isolate G relative to isolate A were sequenced by Sanger sequencing in 10 unrelated C. glabrata echinocandin-resistant clinical isolates containing the resistance mutation FKS2 T1987C/Fks2 S663P. Synonymous mutations are in black font; non-synonymous mutations are in red with amino acid mutations listed in parentheses. Sequences were compared to both the reference CBS138 sequence as well as a control sample sequenced from the laboratory isolate BG2 (CgLC1272).CC BY · PubMed Central
Figure 5 The CDC6 A511G (Cdc6 K171E) mutation uncovered in clinical isolate C imparts a small increase in echinocandin resistance in C. glabrata. The mutant allele of CDC6 that was identified in clinical isolate C and accompanied a small increase in echinocandin resistance, or a wild-type allele of CDC6 cloned from the early sensitive isolate A, was expressed on a plasmid under the control of its native promoter and introduced as the only copy of CDC6 in a laboratory strain of C. glabrata. Caspofungin resistance of two independent transformants of strains harbouring the mutant or wild-type CDC6 allele was assessed using an MIC assay. Assays were performed in synthetic defined medium at 30°C for 72 hours. Data was analyzed as in Figure 1.
Figure 5 The CDC6 A511G (Cdc6 K171E) mutation uncovered in clinical isolate C imparts a small increase in echinocandin resistance in C. glabrata. The mutant allele of CDC6 that was identified in clinical isolate C and accompanied a small increase in echinocandin resistance, or a wild-type allele of CDC6 cloned from the early sensitive isolate A, was expressed on a plasmid under the control of its native promoter and introduced as the only copy of CDC6 in a laboratory strain of C. glabrata. Caspofungin resistance of two independent transformants of strains harbouring the mutant or wild-type CDC6 allele was assessed using an MIC assay. Assays were performed in synthetic defined medium at 30°C for 72 hours. Data was analyzed as in Figure 1.CC BY · PubMed Central
Figure 6 Hsp90 plays a critical role in echinocandin resistance of C. glabrata clinical isolates. (A) Pharmacological inhibition of Hsp90 with geldanamycin or radicicol reduces caspofungin resistance of C. glabrata clinical isolates in an MIC assay. Isolates are arranged in the same order as they were recovered from a patient who was on caspofungin treatment, where isolate A was recovered pre-treatment and isolate G was recovered after multiple rounds of caspofungin treatment. Assays were done in synthetic defined medium at 30°C for 72 hours. Data was analyzed as in Figure 1. (B) Genetic depletion of Hsp90 confers hypersusceptibility to caspofungin. Growth of the late, echinocandin-resistant clinical isolate G and its derivative in which HSP90 expression is driven by the methionine-repressible MET3 promoter was assessed in a checkerboard format with a gradient of caspofungin and a gradient of methionione. Methionine had no impact on caspofungin resistance of isolate G, but increased the susceptibility of the MET3p-HSP90 strain in a concentration-dependent manner.
Figure 6 Hsp90 plays a critical role in echinocandin resistance of C. glabrata clinical isolates. (A) Pharmacological inhibition of Hsp90 with geldanamycin or radicicol reduces caspofungin resistance of C. glabrata clinical isolates in an MIC assay. Isolates are arranged in the same order as they were recovered from a patient who was on caspofungin treatment, where isolate A was recovered pre-treatment and isolate G was recovered after multiple rounds of caspofungin treatment. Assays were done in synthetic defined medium at 30°C for 72 hours. Data was analyzed as in Figure 1. (B) Genetic depletion of Hsp90 confers hypersusceptibility to caspofungin. Growth of the late, echinocandin-resistant clinical isolate G and its derivative in which HSP90 expression is driven by the methionine-repressible MET3 promoter was assessed in a checkerboard format with a gradient of caspofungin and a gradient of methionione. Methionine had no impact on caspofungin resistance of isolate G, but increased the susceptibility of the MET3p-HSP90 strain in a concentration-dependent manner.CC BY · PubMed Central
Figure 7 Calcineurin is a key-mediator of Hsp90-dependent echinocandin resistance of C. glabrata. (A) Genetic or pharmacological compromise of calcineurin function reduces echinocandin resistance of the clinical isolates. Deletion of the regulatory subunit of calcineurin, CNB1, required for calcineurin function reduces caspofungin resistance in resistant clinical isolates. Pharmacological inhibition of calcineurin with either cyclosporin A or FK506 also reduces caspofungin resistance. The assay was performed and analyzed as in Figure 1. (B) Resistance of the laboratory strain BG2 harbouring the T1987C FKS2 mutant allele is reduced upon inhibition of calcineurin with cyclosporin A or inhibition of Hsp90 with geldanamycin. Assays were performed as in part (A) and data was analyzed as in Figure 1.
Figure 7 Calcineurin is a key-mediator of Hsp90-dependent echinocandin resistance of C. glabrata. (A) Genetic or pharmacological compromise of calcineurin function reduces echinocandin resistance of the clinical isolates. Deletion of the regulatory subunit of calcineurin, CNB1, required for calcineurin function reduces caspofungin resistance in resistant clinical isolates. Pharmacological inhibition of calcineurin with either cyclosporin A or FK506 also reduces caspofungin resistance. The assay was performed and analyzed as in Figure 1. (B) Resistance of the laboratory strain BG2 harbouring the T1987C FKS2 mutant allele is reduced upon inhibition of calcineurin with cyclosporin A or inhibition of Hsp90 with geldanamycin. Assays were performed as in part (A) and data was analyzed as in Figure 1.CC BY · PubMed Central
Figure 8 Caspofungin induces FKS2 expression in a calcineurin- and Hsp90-dependent manner in C. glabrata. (A) Caspofungin induces expression of CNB1, which encodes the regulatory subunit of calcineurin, and FKS2, which encodes 1,3-β-D-glucan synthases, in the late clinical isolate G but not in its derivative lacking CNB1. Transcript levels of the regulatory subunit CNB1 (left panel) and FKS2 (right panel) were measured by quantitative RT-PCR after growth in rich medium at 30°C for one hour with or without caspofungin (CF) at 120 ng/ml, as indicated. Transcript levels are normalized relative to ACT1. Expression is relative to the untreated sample, which was set to 1. Data are means ± standard deviation for triplicate samples and representative of two independent biological replicate experiments. Three asterisks indicate P<0.001 (ANOVA, Bonferroni's Multiple Comparison Test). (B) Caspofungin induces expression of resistance determinant FKS2 in the late clinical isolate G, but induction is reduced in its MET3p-HSP90 derivative (P<0.001). Transcript levels of HSP90 and FKS2 were measured by quantitative RT-PCR after growth in conditions listed in (A), and in the presence of methionine at a concentration that had minimal impact on growth (0.25 µg/ml). Data are analyzed as in (A).
Figure 8 Caspofungin induces FKS2 expression in a calcineurin- and Hsp90-dependent manner in C. glabrata. (A) Caspofungin induces expression of CNB1, which encodes the regulatory subunit of calcineurin, and FKS2, which encodes 1,3-β-D-glucan synthases, in the late clinical isolate G but not in its derivative lacking CNB1. Transcript levels of the regulatory subunit CNB1 (left panel) and FKS2 (right panel) were measured by quantitative RT-PCR after growth in rich medium at 30°C for one hour with or without caspofungin (CF) at 120 ng/ml, as indicated. Transcript levels are normalized relative to ACT1. Expression is relative to the untreated sample, which was set to 1. Data are means ± standard deviation for triplicate samples and representative of two independent biological replicate experiments. Three asterisks indicate P<0.001 (ANOVA, Bonferroni's Multiple Comparison Test). (B) Caspofungin induces expression of resistance determinant FKS2 in the late clinical isolate G, but induction is reduced in its MET3p-HSP90 derivative (P<0.001). Transcript levels of HSP90 and FKS2 were measured by quantitative RT-PCR after growth in conditions listed in (A), and in the presence of methionine at a concentration that had minimal impact on growth (0.25 µg/ml). Data are analyzed as in (A).CC BY · PubMed Central
Figure 9 Clinical isolate F is a petite mutant and is refractory to the synergy between caspofungin and Hsp90 or calcineurin inhibitors. (A) Clinical isolate F is a petite mutant. Each clinical isolate from the C. glabrata echinocandin-resistant series was struck onto rich yeast extract-peptone-dextrose (YPD) agar medium or yeast extract-peptone-glycerol (YPG) agar medium which have glucose or glycerol as the sole carbon source, respectively. Isolate F produces small, transparent colonies on YPD and is unable to grow on YPG. Petite mutants have lost their mitochondrial function, are unable to respire, and therefore unable to utilize non-fermentable carbon sources. Isolates were patched onto the plates and photographed after incubation in the dark at 30°C for 24 hours. (B) The petite phenotype is not intrinsically involved in caspofungin (CF) resistance of C. glabrata clinical isolates. Petite mutants were generated from early clinical isolate A by growth in 10 µg/ml ethidium bromide for 48 hours in the dark and were identified based on morphology and inability to grow on YPG. CF resistance was then compared to resistant petite clinical isolate F in an MIC assay along with inhibition of Hsp90 with 20 µM geldanamycin (GdA) or inhibition of calcineurin with 10 µM cyclosporin A (CsA). (C) CF-resistant petite mutants of C. glabrata are refractory to the synergy between caspofungin and inhibitors of Hsp90 or calcineurin. Petite mutants were generated from late clinical isolate G as in part (B). CF resistance was then compared to the resistant petite clinical isolate F in an MIC assay with or without pharmacological inhibition of Hsp90 with 20 µM GdA or pharmacological inhibition of calcineurin with 10 µM CsA. (D) CF resistance of petite mutants of C. glabrata is dependent on calcineurin. Petite mutants were generated from the late clinical isolate G cnb1Δ deletion mutant as in part (B). Synergy between CF and Hsp90 inhibition with GdA (20 µM) or calcineurin inhibition with CsA (10 µM) was tested. MIC assays were performed and analyzed as in Figure 1.
Figure 9 Clinical isolate F is a petite mutant and is refractory to the synergy between caspofungin and Hsp90 or calcineurin inhibitors. (A) Clinical isolate F is a petite mutant. Each clinical isolate from the C. glabrata echinocandin-resistant series was struck onto rich yeast extract-peptone-dextrose (YPD) agar medium or yeast extract-peptone-glycerol (YPG) agar medium which have glucose or glycerol as the sole carbon source, respectively. Isolate F produces small, transparent colonies on YPD and is unable to grow on YPG. Petite mutants have lost their mitochondrial function, are unable to respire, and therefore unable to utilize non-fermentable carbon sources. Isolates were patched onto the plates and photographed after incubation in the dark at 30°C for 24 hours. (B) The petite phenotype is not intrinsically involved in caspofungin (CF) resistance of C. glabrata clinical isolates. Petite mutants were generated from early clinical isolate A by growth in 10 µg/ml ethidium bromide for 48 hours in the dark and were identified based on morphology and inability to grow on YPG. CF resistance was then compared to resistant petite clinical isolate F in an MIC assay along with inhibition of Hsp90 with 20 µM geldanamycin (GdA) or inhibition of calcineurin with 10 µM cyclosporin A (CsA). (C) CF-resistant petite mutants of C. glabrata are refractory to the synergy between caspofungin and inhibitors of Hsp90 or calcineurin. Petite mutants were generated from late clinical isolate G as in part (B). CF resistance was then compared to the resistant petite clinical isolate F in an MIC assay with or without pharmacological inhibition of Hsp90 with 20 µM GdA or pharmacological inhibition of calcineurin with 10 µM CsA. (D) CF resistance of petite mutants of C. glabrata is dependent on calcineurin. Petite mutants were generated from the late clinical isolate G cnb1Δ deletion mutant as in part (B). Synergy between CF and Hsp90 inhibition with GdA (20 µM) or calcineurin inhibition with CsA (10 µM) was tested. MIC assays were performed and analyzed as in Figure 1.CC BY · PubMed Central
Figure 10 Fungal burden of the C. glabrata clinical isolate series and MET3p-HSP90 strain in a murine model of disseminated infection. CD1 mice were infected with an inoculum of 2×107 cells via lateral tail vein injection. One asterisk indicates P<0.05, two indicates P<0.01, and three indicates P<0.001 (Kruskal-Wallis Test, Dunn's Multiple Comparison). Fungal burden was measured in the (A) kidney and (B) spleen 7 days post infection. Organs of mice infected with isolate F were sterile.
Figure 10 Fungal burden of the C. glabrata clinical isolate series and MET3p-HSP90 strain in a murine model of disseminated infection. CD1 mice were infected with an inoculum of 2×107 cells via lateral tail vein injection. One asterisk indicates P<0.05, two indicates P<0.01, and three indicates P<0.001 (Kruskal-Wallis Test, Dunn's Multiple Comparison). Fungal burden was measured in the (A) kidney and (B) spleen 7 days post infection. Organs of mice infected with isolate F were sterile.CC BY · PubMed Central

Verification

Claims the paper makes

26 Valid · 2 Not valid · 8 Not checked · 151 Own results and interpretations

124 more claims · 11 with their cited sources checked

Create a free account to see all 187 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 39
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

23 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 133 references

Research works printed but not linked: 1

  1. 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, Third Edition, Document M27-A3

Cited by

See all 205

Metadata

Authors
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E.
Affiliations
  • University of Toronto (CA)
  • Stanford University (US)
  • Duke Medical Center (US)
  • Mount Sinai Hospital (CA)
  • University of Alberta (CA)
Corresponding author
Cowen, Leah E.
Venue
PLoS Pathogens
Published
2012-05-17
Volume
8
Issue
5
Pages
e1002718
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W2019892034
Cited by
205
References
133
Citations by year
2026: 15 · 2025: 15 · 2024: 10 · 2023: 11 · 2022: 11 · 2021: 15 · 2020: 15 · 2019: 14 · 2018: 22 · 2017: 16 · 2016: 14 · 2015: 18 · 2014: 22 · 2013: 4 · 2012: 3
FWCI
10.51
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure (University of Bath) (publishedVersion, cc-by)
  • Bristol Research (University of Bristol) (publishedVersion)
  • The University of Bath Online Publications Store (The University of Bath) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Explore Bristol Research (submittedVersion)
Funders
  • Burroughs Wellcome Fund
  • University of Toronto
  • National Institutes of Health
  • Center for AIDS Research, Duke University (AI 064518)
  • Center for AIDS Research, University of Washington
  • Canadian Institutes of Health Research
  • Natural Sciences and Engineering Research Council of Canada (355965-2009)
  • National Institute of Allergy and Infectious Diseases (R01AI050438, P30AI064518)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
echinocandin resistance, Candida glabrata, caspofungin, FKS2, CDC6, Cdc55, HSP90, calcineurin, fitness cost, compensatory mutations, drug resistance evolution, petite mutants, mitochondrial respiration, Hsp90 inhibitors, calcineurin inhibitors, antifungal resistance
MeSH terms
Caspofungin, Antifungal Agents, Base Sequence, Female, Fungal Proteins, Glucosyltransferases, Humans, Microbial Sensitivity Tests, Middle Aged, Polymorphism, Genetic, Genome, Fungal, Sequence Analysis, DNA, HSP90 Heat-Shock Proteins, Evolution, Molecular, Calcineurin, Drug Resistance, Fungal, Candida glabrata, Echinocandins, Lipopeptides, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata. https://app.cochat.ai/papers/10.1371/journal.ppat.1002718
The paper
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012). Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata. PLoS Pathogens. https://doi.org/10.1371/journal.ppat.1002718

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.